Sayed Mehdi H. Hamadani, MD
Professor
Locations
- Froedtert Hospital
- Clinical Cancer Center - Froedtert Hospital
Specialties
- Hematology
- Medical Oncology
Languages
- English, Urdu, Hindi, Punjabi
Clinical Cancer Center - Froedtert Hospital
Education
- MD - Doctor of Medicine
Biography
Dr. Hamadani is a professor of medicine and chief of hematologic malignancies at the Medical College of Wisconsin (MCW) in Milwaukee, WI. He serves as the Associate Director of Clinical Research at the MCW Clinical Cancer Center and holds the Cancer Center Scholar Endowed Chair. Dr. Hamadani graduated with honors from King Edward Medical College (Pakistan), in 2001. He completed internal medicine residency from the University of Oklahoma followed by a fellowship in Hematology/Oncology at The Ohio State University. He is considered an international key opinion leader in the fields of hematopoietic cell transplantation, cellular therapy and lymphoid malignancies. He has authored over 450 peer-reviewed publications. As the Principal Protocol Officer for BMT CTN and Co-PI of MCW LAPS Grant he has extensive experience in clinical trial design and has been involved in the development and execution of several practice changing transplant clinical trials. He chairs the ASTCT Committee on Practice Guidelines and served as the Secretary of American Society for Transplant and Cellular Therapies (2024-26). His key areas of search include graft-versus-host disease (GvHD), developmental therapeutics for lymphoid malignancies and hematopoietic cell transplantation. His clinical expertise includes lymphomas, transplant, and CAR-T cell therapies. He considers mentoring junior faculty and trainees as his top-most priority.
Research Interests
Publications
-
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
(Herrera AF, Ansell SM, Zinzani PL, Radford J, Maddocks K, Pinto A, Collins GP, Bachanova V, Bartlett NL, Bence-Bruckler I, Hamadani M, Kline J, Mayer J, Savage KJ, Advani RH, Caimi PF, Casasnovas RO, Feldman T, Hess B, Bastos-Oreiro M, Iyengar S, Szomor Á, Townsend W, André M, Dyczkowski J, Havenith K, Toukam M, Pantano S, Cruz HG, Wang L, Negievich Y, Lucero M, Wuerthner J, Carlo-Stella C.) Blood Adv. 2025 Dec 09;9(23):6205-6217 PMID: 40811783 PMCID: PMC12745010 08/14/2025
-
(Ustun C, Zhang MJ, Peterson A, Baek A, Agha M, Alkhateeb H, Chhabra S, Coltoff A, de Lima M, Gandhi A, Ho V, Kassim A, Lin A, Gowda L, Borthakur G, DeAngelo DJ, McGuirk J, Mensah F, Nadiminti KV, Nishihori T, Pantin J, Trunk A, Uberti J, Marcucci G, Gotlib J, Akin C, Hamadani M, Pullarkat V, Valent P, Grunwald M, Juckett M, Oran B, Saber W, Burns LJ.) Br J Haematol. 2025 Dec;207(6):2486-2495 PMID: 40983528 PMCID: PMC12519450 SCOPUS ID: 2-s2.0-105016816308 09/23/2025
-
CD19 directed CAR T therapy for intravascular large B-cell lymphoma.
(Patel J, Gopal A, Cherniawsky H, Ram R, Kamble R, Hamadani M.) Haematologica. 2025 Nov 06 PMID: 41195517 11/06/2025
-
(Salles G, Fox CP, Hamadani M, Wang A, Sail K, Alshreef A, Moran M, Mutebi A, Blaedel J, Chirikov V, Thieblemont C.) Clin Lymphoma Myeloma Leuk. 2025 Nov;25(11):e986-e994.e4 PMID: 40903324 PMCID: PMC12425561 09/04/2025
-
Reduced-intensity conditioning for allogeneic transplantation in classical Hodgkin lymphoma.
(Narvel H, Ahmed G, Hamadani M.) Expert Rev Hematol. 2025 Nov;18(11):935-944 PMID: 40767562 08/06/2025
-
(Levis MJ, Hamadani M, Chen YB.) Blood Adv. 2025 Oct 29 PMID: 41160800 10/29/2025
-
(Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar OS, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, Jurdi NE, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Pérez WS, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M.) Transplant Cell Ther. 2025 Oct 07 PMID: 41027557 PMCID: PMC12606686 SCOPUS ID: 2-s2.0-105018107118 10/01/2025
-
CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma: A CIBMTR Analysis.
(Gauthier J, Ahn KW, Patel J, Lian Q, Badawy S, Cairo MS, Delgado J, Grover N, Haverkos B, de Lima M, Malone A, Mussetti A, Nieto Y, Pawarode A, Pearson L, Solh M, Sureda A, Tun AM, Wudhikarn K, Yamshon S, Shadman M, Turtle CJ, Hamadani M, Herrera AF.) Am J Hematol. 2025 Oct;100(10):1792-1802 PMID: 40785644 PMCID: PMC12608806 SCOPUS ID: 2-s2.0-105012974565 08/11/2025
-
CD19 Directed CAR T Therapy for Transformed Follicular Lymphoma: A CIBMTR Analysis.
(Thiruvengadam SK, Ahn KW, Patel J, Lian Q, Hertzberg M, Epperla N, Metheny L, Hong S, Jain T, Aljurf M, Beitinjaneh A, Vaughn J, Gopal A, Iqbal M, Wirk B, Manjappa S, Oliver C, Mohty R, Shadman M, Turtle C, Hamadani M, Herrera AF.) Am J Hematol. 2025 Oct;100(10):1803-1812 PMID: 40762207 PMCID: PMC12582634 SCOPUS ID: 2-s2.0-105012595303 08/05/2025
-
(Hamby M, Egleston B, Frosch Z, Steiner R, Noy A, Carvajal V, Chong E, Tolu S, Jean-Louis G, Amengual J, Patel R, Ahmed S, Sharp J, Voorhees T, Baiocchi R, Ramirez-Gamero A, Castillo J, Hamburger E, Dittus C, Nizamuddin I, Mehta-Shah N, Dar NNT, Sandoval-Sus J, Rojek A, Riedell P, Khan N, Danilov A, Solipuram V, Rubinstein P, Ariotti A, Suneja G, Vartanov A, Milrod C, Olszewski A, Smilnak G, Ayers E, Desai S, Rhodes J, Magarelli G, Feldman T, Pellon M, Aboulafia D, Bae W, Galvez C, Bhatlapenumarthi V, Hamadani M, Barta S.) Res Sq. 2025 Sep 30 PMID: 41255989 PMCID: PMC12622178 11/19/2025
-
(Shahzad M, Amin MK, Irfan S, Ahsan R, Qasim H, Javed MJ, McGuirk M, Chaudhary SG, Anwar I, Yacoub A, Singh AK, Hamadani M, Mcguirk JP, Mushtaq MU.) Clin Lymphoma Myeloma Leuk. 2025 Aug 17 PMID: 40930937 09/11/2025
-
(Shahzad M, Amin MK, Irfan S, Vyas A, Ahsan R, Chaudhary SG, Anwar I, McGuirk M, Iftikhar R, Abdelhakim H, Singh AK, Hamadani M, Mcguirk JP, Mushtaq MU.) Clin Lymphoma Myeloma Leuk. 2025 Aug 17 PMID: 40930936 09/11/2025